Lung Adenocarcinoma-Induced Leptomeningeal Metastasis Complicated by Lemierre Syndrome: A Case Study and Literature Review - Takeaways - MDSpire

Lung Adenocarcinoma-Induced Leptomeningeal Metastasis Complicated by Lemierre Syndrome: A Case Study and Literature Review

  • By

  • Xiaoxia Yang

  • Jingang Han

  • Zhi Yu

  • Jianhua Nian

  • Jie Chen

  • January 14, 2026

  • 0 min

Share

  • 1

    Lemierre syndrome is a rare condition characterized by oropharyngeal infection, internal jugular vein thrombosis, and anaerobic pathogens.

  • 2

    Lung adenocarcinoma is a leading cause of cancer-related mortality, with significant metastatic potential, including leptomeningeal metastasis.

  • 3

    The co-occurrence of Lemierre syndrome and lung adenocarcinoma-related leptomeningeal metastasis is extremely rare and presents diagnostic challenges.

  • 4

    The patient in this case study developed Lemierre syndrome followed by metastatic lung adenocarcinoma, highlighting the complexity of dual diagnoses.

  • 5

    Timely diagnosis and treatment of Lemierre syndrome are crucial to prevent severe complications and improve patient outcomes.

Original Source(s)

Lung Adenocarcinoma-Induced Leptomeningeal Metastasis Complicated by Lemierre Syndrome: A Case Study and Literature Review

  • by Xiaoxia Yang, Jingang Han, Zhi Yu, Jianhua Nian, Jie Chen

  • January 14, 2026

Related Content

Development and validation of a predictive nomogram for leptomeningeal metastasis risk in NSCLC brain metastases: role of tumor location, driver mutations, and stereotactic radiosurgery

Rechallenge with Ruxolitinib Following BRAF/MEK Inhibitor-Induced HLH-Like Hyperinflammatory Syndrome in a Patient with BRAF V600E-Mutated Lung Adenocarcinoma: A Case Study

Temple Lung Center | Enrolling Clinical Trials

The Temple Lung Center conducts one of the most comprehensive lung disease clinical trials programs in the country. Our advancements in basic, translational and clinical research are changing lung disease treatment. By pioneering effective therapies, we bring hope to patients with serious and debilitating lung diseases.

  • by

  • March 23, 2026

  • 5 min